TNGX Tango Therapeutics Inc

Price (delayed)

$9.74

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.11

Enterprise value

$1.02B

tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million ...

Highlights
The gross profit rose by 50% year-on-year
The revenue rose by 50% YoY
Tango Therapeutics's EPS has increased by 12% YoY but it has decreased by 2.8% QoQ
The company's net income fell by 10% QoQ

Key stats

What are the main financial stats of TNGX
Market
Shares outstanding
106.85M
Market cap
$1.04B
Enterprise value
$1.02B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.93
Price to sales (P/S)
28.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.34
Earnings
Revenue
$37.23M
EBIT
-$111.48M
EBITDA
-$105.36M
Free cash flow
-$122.03M
Per share
EPS
-$1.11
Free cash flow per share
-$1.13
Book value per share
$2.48
Revenue per share
$0.34
TBVPS
$3.76
Balance sheet
Total assets
$406.22M
Total liabilities
$141.77M
Debt
$38.24M
Equity
$264.45M
Working capital
$309.25M
Liquidity
Debt to equity
0.14
Current ratio
8.23
Quick ratio
8.03
Net debt/EBITDA
0.22
Margins
EBITDA margin
-283%
Gross margin
100%
Net margin
-299.9%
Operating margin
-338.8%
Efficiency
Return on assets
-27.6%
Return on equity
-44.3%
Return on invested capital
-33.5%
Return on capital employed
-30.7%
Return on sales
-299.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TNGX stock price

How has the Tango Therapeutics stock price performed over time
Intraday
-1.52%
1 week
-1.02%
1 month
-3.56%
1 year
200.62%
YTD
-1.62%
QTD
13.52%

Financial performance

How have Tango Therapeutics's revenue and profit performed over time
Revenue
$37.23M
Gross profit
$37.23M
Operating income
-$126.14M
Net income
-$111.65M
Gross margin
100%
Net margin
-299.9%
The gross profit rose by 50% year-on-year
The revenue rose by 50% YoY
The net margin has grown by 33% YoY but it has contracted by 8% from the previous quarter
The operating margin is up by 27% year-on-year but it is down by 8% since the previous quarter

Growth

What is Tango Therapeutics's growth rate over time

Valuation

What is Tango Therapeutics stock price valuation
P/E
N/A
P/B
3.93
P/S
28.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.34
Tango Therapeutics's EPS has increased by 12% YoY but it has decreased by 2.8% QoQ
The stock's P/B is 33% more than its last 4 quarters average of 3.0
The equity has increased by 16% YoY and by 4.5% QoQ
The revenue rose by 50% YoY
TNGX's price to sales (P/S) is 33% higher than its last 4 quarters average of 21.6

Efficiency

How efficient is Tango Therapeutics business performance
Tango Therapeutics's return on sales has increased by 33% YoY but it has decreased by 8% QoQ
The ROA is down by 10% since the previous quarter and by 9% year-on-year
TNGX's ROIC is down by 9% from the previous quarter
The ROE is down by 5% since the previous quarter and by 4.7% year-on-year

Dividends

What is TNGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TNGX.

Financial health

How did Tango Therapeutics financials performed over time
The total assets is 187% more than the total liabilities
Tango Therapeutics's quick ratio has increased by 29% YoY and by 9% from the previous quarter
The current ratio has grown by 29% YoY and by 9% from the previous quarter
The debt is 86% less than the equity
The debt to equity has declined by 22% year-on-year and by 7% since the previous quarter
The equity has increased by 16% YoY and by 4.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.